Sartorius (OTCMKTS:SARTF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday. The brokerage presently has a $150.00 price objective on the stock. Zacks Investment Research‘s price target suggests a potential upside of 11.77% from the company’s previous close.
According to Zacks, “Sartorius AG is a pharmaceutical and laboratory equipment supplier. The company manufactures equipment for biomolecular and microbial separations, cell culture, concentration, fermentation and purification. Sartorius AG is headquartered in Goettingen, Germany. “
Shares of SARTF opened at $134.21 on Wednesday. Sartorius has a 12-month low of $124.00 and a 12-month high of $149.00. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.00 and a current ratio of 1.62. The stock has a market cap of $5.02 billion, a P/E ratio of 71.77 and a beta of 0.08.
Sartorius Company Profile
There is no company description available for Sartorius AG.
Featured Story: Book Value Of Equity Per Share – BVPS Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.